Department of Dermatology, Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Rd, Hangzhou, Zhejiang 310009, China.
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620926800. doi: 10.1177/1753466620926800.
Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe group patients. Given the similarities of clinical features and pathogenesis between toxic epidermal necrolysis (TEN) and COVID-19, we hypothesize that the application of etanercept, an inhibitor of TNFα, could attenuate disease progression in severe group COVID-19 patients by suppressing systemic auto-inflammatory responses.
在 COVID-19 患者中，尤其是在重症组中，观察到炎症细胞因子（如肿瘤坏死因子-α（TNFα）和白细胞介素-6（IL-6））增加。细胞因子风暴现象可能是肺泡上皮细胞凋亡的中心诱导剂，导致重症组患者病情迅速进展。鉴于中毒性表皮坏死松解症（TEN）和 COVID-19 在临床特征和发病机制上的相似性，我们假设 TNFα抑制剂依那西普的应用可以通过抑制全身自身炎症反应来减轻重症 COVID-19 患者的疾病进展。
